MX2019003058A - Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1). - Google Patents
Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1).Info
- Publication number
- MX2019003058A MX2019003058A MX2019003058A MX2019003058A MX2019003058A MX 2019003058 A MX2019003058 A MX 2019003058A MX 2019003058 A MX2019003058 A MX 2019003058A MX 2019003058 A MX2019003058 A MX 2019003058A MX 2019003058 A MX2019003058 A MX 2019003058A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- monoclonal antibodies
- programmed death
- novel monoclonal
- present
- Prior art date
Links
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención proporciona anticuerpos monoclonales PD-1, particularmente anticuerpos monoclonales humanos de PD-1, que se unen específicamente a PD-1 con alta afinidad y comprenden una cadena pesada y una cadena ligera. La presente invención proporciona además una secuencia de ácido nucleico que codifica los anticuerpos de la invención, los vectores de clonación o expresión, las células hospederas y los métodos para expresar o aislar los anticuerpos. También se proporcionan inmunoconjugados, composiciones terapéuticas que comprenden los anticuerpos de la invención. La invención también proporciona métodos para tratar diversos cánceres con anticuerpos anti-PD-1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/099576 WO2018053709A1 (en) | 2016-09-21 | 2016-09-21 | The novel monoclonal antibodies to programmed death 1 (pd-1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003058A true MX2019003058A (es) | 2019-11-28 |
Family
ID=61690082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003058A MX2019003058A (es) | 2016-09-21 | 2016-09-21 | Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1). |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11414487B2 (es) |
| EP (2) | EP3515938B8 (es) |
| JP (2) | JP7101169B2 (es) |
| KR (2) | KR102527160B1 (es) |
| AU (1) | AU2016423559C1 (es) |
| BR (1) | BR112019005316A2 (es) |
| CA (1) | CA3037407C (es) |
| DK (1) | DK3515938T3 (es) |
| ES (1) | ES3017957T3 (es) |
| FI (1) | FI3515938T3 (es) |
| HR (1) | HRP20250400T1 (es) |
| HU (1) | HUE071253T2 (es) |
| IL (1) | IL265525A (es) |
| LT (1) | LT3515938T (es) |
| MX (1) | MX2019003058A (es) |
| PL (1) | PL3515938T3 (es) |
| PT (1) | PT3515938T (es) |
| RS (1) | RS66679B1 (es) |
| RU (1) | RU2757316C2 (es) |
| SA (1) | SA519401370B1 (es) |
| SI (1) | SI3515938T1 (es) |
| SM (1) | SMT202500148T1 (es) |
| WO (1) | WO2018053709A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3334763T (pt) | 2015-08-11 | 2024-10-28 | Wuxi Biologics Ireland Ltd | Novos anticorpos anti-pd-1 |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| RS66679B1 (sr) * | 2016-09-21 | 2025-05-30 | Cstone Pharmaceuticals | Monoklonska antitela za programiranu smrt 1 (pd-1) |
| MX2019004834A (es) | 2016-11-02 | 2019-06-20 | Jounce Therapeutics Inc | Anticuerpos de pd-1 y usos de estos. |
| PE20250757A1 (es) | 2017-08-03 | 2025-03-13 | Amgen Inc | Muteinas de interleucina 21 y metodos de tratamiento |
| KR20200110358A (ko) | 2018-01-12 | 2020-09-23 | 암젠 인크 | 항-pd-1 항체 및 치료 방법 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CA3097062A1 (en) * | 2018-04-15 | 2019-10-24 | Salubris (Chengdu) Biotech Co., Ltd | Antibodies binding pd-1 and uses thereof |
| WO2019204132A1 (en) * | 2018-04-15 | 2019-10-24 | Biosion Inc. | Antibodies binding pd-1 and uses thereof |
| CN109160949B (zh) * | 2018-07-23 | 2021-05-14 | 中国医学科学院血液病医院（血液学研究所） | 一种鼠抗人pd-1单克隆抗体及应用 |
| WO2020216348A1 (en) * | 2019-04-26 | 2020-10-29 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific antibodies against pd-1 and lag-3 |
| JP2022534889A (ja) | 2019-05-24 | 2022-08-04 | ファイザー・インコーポレイテッド | Ｃｄｋ阻害剤を使用した組合せ療法 |
| KR102866812B1 (ko) * | 2019-09-25 | 2025-10-02 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 항-pd-l1 항체 |
| WO2021093764A1 (en) * | 2019-11-11 | 2021-05-20 | Cstone Pharmaceuticals (Suzhou) Co., Ltd. | Pharmaceutical combination and use thereof |
| WO2021110122A1 (zh) * | 2019-12-05 | 2021-06-10 | 基石药业（苏州）有限公司 | Cdk4/6抑制剂的组合疗法 |
| EP4157876B1 (en) | 2020-05-26 | 2024-09-04 | Boehringer Ingelheim International GmbH | Anti-pd-1 antibodies |
| US20230331848A1 (en) * | 2020-08-31 | 2023-10-19 | Biosion Inc. | Pd-1 binding antibodies and uses thereof |
| WO2022068919A1 (zh) * | 2020-09-30 | 2022-04-07 | 正大天晴康方(上海)生物医药科技有限公司 | 结合pd-1抗体的肽及其应用 |
| WO2022118197A1 (en) | 2020-12-02 | 2022-06-09 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| EP4289866A4 (en) * | 2021-02-04 | 2025-05-14 | Genuv Inc. | ANTI-PD-1 ANTIBODY AND ITS USE |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| CN116036266A (zh) * | 2022-12-28 | 2023-05-02 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗结肠癌患者的药物中的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006021955A2 (en) | 2004-08-23 | 2006-03-02 | Mor Research Applications Ltd. | Use of bat monoclonal antibody for immunotherapy |
| EP2439273B1 (en) * | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| US7662965B2 (en) * | 2006-01-26 | 2010-02-16 | Cornerstone Therapeutics, Inc. | Anabaseine derivatives, pharmaceutical compositions and method of use thereof |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP2831114B1 (en) * | 2012-03-30 | 2019-05-08 | Eisai R&D Management Co., Ltd. | Tem-1 diagnostic antibodies |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| CN105330740B (zh) | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| WO2016077397A2 (en) | 2014-11-11 | 2016-05-19 | Sutro Biopharma, Inc. | Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2016127179A2 (en) * | 2015-02-06 | 2016-08-11 | Kadmon Corporation, Llc | Immunomodulatory agents |
| PT3334763T (pt) | 2015-08-11 | 2024-10-28 | Wuxi Biologics Ireland Ltd | Novos anticorpos anti-pd-1 |
| DK3368572T3 (da) | 2015-10-02 | 2022-08-08 | Symphogen As | Anti-pd-1-antistoffer og -sammensætninger |
| RS66679B1 (sr) * | 2016-09-21 | 2025-05-30 | Cstone Pharmaceuticals | Monoklonska antitela za programiranu smrt 1 (pd-1) |
| CN109575139A (zh) * | 2017-09-29 | 2019-04-05 | 上海药明生物技术有限公司 | 针对表皮生长因子受体和程序性死亡受体的双特异抗体 |
| WO2021093764A1 (en) * | 2019-11-11 | 2021-05-20 | Cstone Pharmaceuticals (Suzhou) Co., Ltd. | Pharmaceutical combination and use thereof |
-
2016
- 2016-09-21 RS RS20250329A patent/RS66679B1/sr unknown
- 2016-09-21 FI FIEP16916449.8T patent/FI3515938T3/fi active
- 2016-09-21 AU AU2016423559A patent/AU2016423559C1/en active Active
- 2016-09-21 BR BR112019005316-6A patent/BR112019005316A2/pt active Search and Examination
- 2016-09-21 HR HRP20250400TT patent/HRP20250400T1/hr unknown
- 2016-09-21 CA CA3037407A patent/CA3037407C/en active Active
- 2016-09-21 HU HUE16916449A patent/HUE071253T2/hu unknown
- 2016-09-21 RU RU2019111277A patent/RU2757316C2/ru active
- 2016-09-21 ES ES16916449T patent/ES3017957T3/es active Active
- 2016-09-21 KR KR1020217020495A patent/KR102527160B1/ko active Active
- 2016-09-21 PL PL16916449.8T patent/PL3515938T3/pl unknown
- 2016-09-21 DK DK16916449.8T patent/DK3515938T3/da active
- 2016-09-21 WO PCT/CN2016/099576 patent/WO2018053709A1/en not_active Ceased
- 2016-09-21 US US16/333,993 patent/US11414487B2/en active Active
- 2016-09-21 SM SM20250148T patent/SMT202500148T1/it unknown
- 2016-09-21 MX MX2019003058A patent/MX2019003058A/es unknown
- 2016-09-21 JP JP2019515471A patent/JP7101169B2/ja active Active
- 2016-09-21 PT PT169164498T patent/PT3515938T/pt unknown
- 2016-09-21 KR KR1020197010353A patent/KR102273634B1/ko active Active
- 2016-09-21 LT LTEPPCT/CN2016/099576T patent/LT3515938T/lt unknown
- 2016-09-21 EP EP16916449.8A patent/EP3515938B8/en active Active
- 2016-09-21 SI SI201631893T patent/SI3515938T1/sl unknown
- 2016-09-21 EP EP24184760.7A patent/EP4450616A3/en active Pending
-
2019
- 2019-03-20 SA SA519401370A patent/SA519401370B1/ar unknown
- 2019-03-20 IL IL265525A patent/IL265525A/en unknown
-
2021
- 2021-04-21 JP JP2021071948A patent/JP2021120378A/ja active Pending
-
2022
- 2022-06-29 US US17/853,606 patent/US20230014722A1/en not_active Abandoned
-
2023
- 2023-08-31 US US18/459,236 patent/US20240101676A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519401370B1 (ar) | الأجسام المضادة وحيدة النسيلة المبتكرة لبروتين الموت المبرمج (pd-1) | |
| CY1123355T1 (el) | Αντισωματα εναντι cd73 και χρησεις εξ αυτων | |
| PH12020551317A1 (en) | Anti-cd73 antibodies and methods of use thereof | |
| ZA201706740B (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
| EP3812398A3 (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| MX2023001791A (es) | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). | |
| MD4716B1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
| PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| NZ738979A (en) | Pd-1 antibodies | |
| SG10201907161YA (en) | Antibodies directed against lymphocyte activation gene 3 (lag-3) | |
| EP3593812A3 (en) | Treatment of cancer using chimeric antigen receptor | |
| MX372817B (es) | Anticuerpos dirigidos contra la proteína muerte programada-1 (pd-1). | |
| PH12019502298A1 (en) | Monoclonal antibody to pd-l1 | |
| JOP20200106A1 (ar) | جسم مضاد أحادي النسيلة مضاد لـ il-5r? | |
| EA201792460A1 (ru) | Связывающие tigit агенты и варианты их применения |